Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually resulting in significant morbidity and up to 650,000 deaths. The influenza burden also results in substantial economic loss. The goal of this program is to develop a therapeutic antibody offering effective treatment with broad heterosubtypic specificity for influenza viruses without inducing resistance. Our therapeutic antibody (3I14) has shown broad neutralizing activity against 14 strains of INFV A Groups 1 and 2 and both prophylactic and therapeutic protection in BALB/c mouse models of H1, H3, H5 and H7 serotypes. This Fast-track proposal is intended to establish a stable expressing cell line for manufacturing, identify an optimal product formulation, characterize the dose response and tolerability of the product in nonclinical studies, and complete the mouse efficacy data package. Completion of these milestones are critical for advancement to IND-enabling studies and clinical development. 3I14 binds the stem of both the uncleaved HA precursor and two mature forms of HA, either after trypsin activation alone or when followed by low-pH trigger. 3I14 prevents both the dissociation of HA1-HA2 and the pH-dependent HA rearrangement necessary for membrane fusion. Targeting the highly conserved HA stem epitope is also expected to drastically reduce the likelihood of viral resistance, a significant barrier to developing effective therapeutics for influenza. Integrated Biotherapeutics (IBT) has extensive experience in preclinical model and antibody product development for infectious diseases. Dr. Holtsberg and his team have extensive experience in providing services to pharma companies over the past 8 years in the development and use of in vitro assays and animal models for testing influenza therapies. This expertise is complimented by a strong strategic partnership with AbViro LLC with subject matter expertise specific to influenza and focus on integrated program management skillsets, extensive knowledge of preclinical product development and clinical science, regulatory expertise, and business and commercialization strategy for broad-spectrum antibodies capable of advancing 3I14 into clinical studies. IBT will also collaborate with MassBiologics, IIT Research Institute (IITRI) and La Jolla Institute for Allergy and Immunology (LJI). MassBiologics offers strong competency in stable cell line and manufacturing process development. IIT Research Institute (IITRI) provides relevant highly pathogenic influenza strains and animal models essential for rigorous evaluation of product efficacy. LJI provides core research functionality with next-generation sequencing capabilities. This development team has successfully advanced another broad-spectrum human monoclonal antibody targeting dengue virus to IND-enabling studies.
Public Health Relevance Statement: Project Narrative Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually and risk of mortality, particularly in young, elderly and immunocompromised populations. Annual vaccination efficacy, currently the most effective control measure, is limited by the requirement for annual reformulation and re-administration with variable efficacy. Potency of existing therapeutic drugs is limited by virus adaptation and emergence of new strains with limited susceptibility to existing drugs. The goal of this program is to develop our lead therapeutic antibody 3I14 offering broad heterosubtypic effective treatment for both Group 1 and 2 influenza A viruses regardless of group specificity, without inducing virus resistance. Completion of the proposed work will position 3I14 for advancement into IND-directed studies.
NIH Spending Category: Antimicrobial Resistance; Biodefense; Biotechnology; Emerging Infectious Diseases; Immunization; Immunotherapy; Infectious Diseases; Influenza; Pneumonia & Influenza; Prevention; Vaccine Related
Project Terms: Agreement; Animal Model; Antibodies; Antiviral Agents; Antiviral resistance; base; Binding; Biological Response Modifier Therapy; Businesses; cell bank; Cell Line; Cessation of life; Chinese Hamster Ovary Cell; Clinical; clinical development; clinical efficacy; Clinical Research; Clinical Sciences; commercialization; Communicable Diseases; Competence; Cyclic GMP; Data; Dengue Virus; Development; Disease Outbreaks; disorder control; Dissociation; Dose; Drug Kinetics; economic impact; Economics; effective therapy; Effectiveness; Elderly; Epitopes; Escape Mutant; Evaluation; experience; Ferrets; Formulation; Goals; Hour; Human; human monoclonal antibodies; Hypersensitivity; Immunocompromised Host; Immunology; Immunotherapeutic agent; In Vitro; in vitro Assay; in vivo; Inbred BALB C Mice; Influenza; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Hemagglutinin; influenza M2; Influenza Therapeutic; influenza virus strain; influenzavirus; Institutes; Intervention; Knowledge; Lead; Legal patent; Licensure; Light; manufacturing process; manufacturing process development; Measures; Membrane Fusion; Monoclonal Antibodies; Morbidity - disease rate; mortality risk; mouse model; Mus; Neuraminidase; neutralizing antibody; next generation sequencing; off-patent; Oseltamivir; pandemic disease; Pathogenicity; Pharmaceutical Preparations; Pharmacology; Phase; Population; Positioning Attribute; pre-clinical; Pre-Clinical Model; Predisposition; prevent; product development; Production; Productivity; programs; prophylactic; Proteins; Research; Research Institute; Resistance; response; Rights; Serotyping; Services; Specificity; stable cell line; stem; Testing; Therapeutic; Therapeutic antibodies; therapeutic evaluation; therapy resistant; Tissues; Toxicology; Treatment Efficacy; Trypsin; United States Food and Drug Administration; universal influenza vaccine; Vaccination; Vaccines; Viral; viral resistance; Virus; Work
